Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.
about
Parkinson's disease: gene therapiesPathway-Specific Dopamine Abnormalities in Schizophrenia.The catecholamine system in health and disease -Relation to tyrosine 3-monooxygenase and other catecholamine-synthesizing enzymes.Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra.Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's diseaseGene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Genomic imprinting of Dopa decarboxylase in heart and reciprocal allelic expression with neighboring Grb10.Complexity of dopamine metabolism.Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging studyAntioxidant and neuroprotective activities of Hyptis suaveolens (L.) Poit. against oxidative stress-induced neurotoxicity.PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment.A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.The beneficial role of thiamine in Parkinson disease.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide.Complex molecular regulation of tyrosine hydroxylase.Perspective on the Road toward Gene Therapy for Parkinson's Disease.Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.Release of membrane-associated L-dopa decarboxylase from human cells.L-Dopa decarboxylase expression profile in human cancer cells.Microstructural changes of brain in patients with aromatic L-amino acid decarboxylase deficiency.Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.A critical review of genetic studies of schizophrenia. II. Molecular genetic studies.Absence of a difference in the neurosecretory activity of supraoptic nucleus vasopressin neurons of neuroleptic-treated schizophrenic patients.Substantia nigra ultrastructural pathology in schizophrenia.Dopamine inhibition of human tyrosine hydroxylase type 1 is controlled by the specific portion in the N-terminus of the enzyme.
P2860
Q26824184-173425DA-81DC-4B6A-87E9-2C06439A5298Q34527656-66B1F7C2-0272-43B5-88AC-0282D6530440Q35115456-94DBF8C8-5F60-46AB-BD1E-506FAF2CAF3CQ35858750-A84D2F2F-225F-4544-9DA3-ABB18DCE58BAQ35875941-17EE0BB5-F5AA-479C-B1B4-B2ADAC7050B8Q35932749-4682BECC-B960-4485-A656-952CE0371F0FQ36150495-B2A1362A-4EA8-40A7-A321-9A12A5DD45B3Q36421141-74AA2613-0132-41B9-A6C3-949B92335738Q36958208-06C8D3E0-CA7A-4BC3-923A-AA73F4B70228Q37256211-8B3951A2-9204-463D-BB21-B74A57C8C01DQ37631698-0EB1E7C2-434C-484D-A1FB-E053B8811283Q37646564-AA6527FF-E148-4A70-A7AB-48A6605CC515Q38014332-3A18994D-EC4A-47C9-B3F5-EC19AFE1A704Q38086654-D0BDEDE7-6B0C-437C-801C-74046DB2D542Q38112216-DD387B86-A062-4AA4-932A-92ECF19CEF78Q38119411-488AA2AF-7B10-4BB0-B8ED-282F6E0D0EE3Q38215359-574F56C2-FE58-4866-BB81-BAB1B519FFEBQ38719576-5D2F715B-BE73-48D5-8D07-B2E7B5E5FF7AQ38834545-620070F6-2DE7-4A35-8A72-2D33CF8A4914Q39464596-205825C3-F551-4125-98B9-06B86306F126Q39561190-CC6D226C-731C-4967-BDE2-3C4C23EBE62DQ39695083-31D6BE6D-5DFC-467C-8F8D-2A1C04FC5EB9Q40469892-AEA0D5B7-2553-4E48-ACC9-96583D78466BQ41271272-0B62309E-4FC2-4513-A9C7-E10E4029527AQ41378723-86F7F47D-970C-4226-BC29-7B84093DFF4DQ46895961-4D43CBA5-B16D-49B7-B567-4D8E5FF7AEB6Q47561103-3DE3D2BC-B9AF-42F3-BF92-4453205ACC68Q54098510-4FE02DE2-7063-4CBA-8FC1-A601CE82EBAB
P2860
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@en
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@nl
type
label
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@en
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@nl
prefLabel
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@en
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@nl
P2093
P921
P356
P1476
Quantification of mRNA of tyro ...... n's disease and schizophrenia.
@en
P2093
P2888
P304
P356
10.1007/BF02250926
P577
1994-01-01T00:00:00Z